Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China

doi:10.1089/derm.2024.0014

科研成果详情

题名	Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China
作者	Zhu, Jiling; Wu, Hanwen; Ye, Yahui; Xu, Qiuyang; Shao, Junyi; Bai, Zicheng; Zhou, Yiwen; Li, Zhenyan; Liu, Jingjing; Li, Zhiming
发表日期	2024-08-20
发表期刊	DERMATITIS 影响因子和分区
语种	英语
原始文献类型	Article ; Early Access
其他关键词	DOUBLE-BLIND ; PLACEBO ; ADULTS
摘要	Background: The efficacy and safety of upadacitinib and dupilumab for atopic dermatitis (AD) in adolescent patients have been proven in clinical trials. However, few daily practice studies comparing agents have been conducted in this patient population. Objectives: This single-center retrospective cohort study aimed to investigate the efficacy, safety, and early relapse after cessation of upadacitinib and dupilumab for moderate-to-severe AD in Chinese adolescents. Methods: A retrospective study collected data on a cohort of 83 adolescent patients receiving upadacitinib or dupilumab from October 2021 to October 2023. This study comprised two main emphases. The first main emphasis involved the treatment phase, where the efficacy and safety of the two treatments were evaluated. Primary endpoints included the proportion of patients achieving an improvement of >= 50%, >= 75%, and >= 90% in Eczema Area and Severity Index (EASI) from baseline (EASI-50, EASI-75, EASI-90) and the proportion of patients achieving Validated Investigator Global Assessment (vIGA) 0/1 at week 4 and week 40. In the second main emphasis, AD recurrence after treatment discontinuation was assessed in the two treatment groups. The median time to relapse was calculated. Results: A total of 83 patients were enrolled. At week 4, the proportion of patients achieving the primary endpoints, including EASI-75 and EASI-90, was substantially higher with upadacitinib than with dupilumab (51.5% vs 14.0% [P < 0.001], 18.2% vs 2.0% [P < 0.05]). However, at week 40, higher proportion of patients on dupilumab were reaching EASI-50 and EASI-75 and vIGA 0/1. After the discontinuation of dupilumab or upadacitinib therapy, the Kaplan-Meier survival curve showed that the median time to relapse was 270 days in the dupilumab group and 18 days in the upadacitinib group. Conclusions: This study demonstrated that upadacitinib has superior short-term efficacy over dupilumab in adolescents with moderate-to-severe AD, whereas dupilumab trends toward better long-term remission over upadacitinib under the condition of treatment discontinuation in some patients.
资助项目	Natural Science Foundation of Zhejiang Province [LY22H160030]
出版者	MARY ANN LIEBERT, INC
ISSN	1710-3568
EISSN	2162-5220
DOI	10.1089/derm.2024.0014
页数	10
WOS类目	Dermatology
WOS研究方向	Dermatology
WOS记录号	WOS:001294443000001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39163276
通讯作者地址	[Liu, Jingjing;Li, Zhiming]Wenzhou Med Univ, Affiliated Hosp 1, Dept Dermatol & Venereol, Wenzhou 325000, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/217494
专题	附属第一医院附属第一医院_皮肤科
通讯作者	Liu, Jingjing; Li, Zhiming
作者单位	Wenzhou Med Univ, Affiliated Hosp 1, Dept Dermatol & Venereol, Wenzhou 325000, Peoples R China
第一作者单位	附属第一医院; 皮肤科
通讯作者单位	附属第一医院; 皮肤科
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Zhu, Jiling,Wu, Hanwen,Ye, Yahui,et al. Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China[J]. DERMATITIS,2024.
APA	Zhu, Jiling., Wu, Hanwen., Ye, Yahui., Xu, Qiuyang., Shao, Junyi., ... & Li, Zhiming. (2024). Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China. DERMATITIS.
MLA	Zhu, Jiling,et al."Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China".DERMATITIS (2024).